Back to Search
Start Over
Adverse Events Induced by Nivolumab Plus Ipilimumab vs. Nivolumab Monotherapy among Cancer Patients: A Systematic Review and Meta-Analysis
- Source :
- Cancer Investigation. 40:777-788
- Publication Year :
- 2022
- Publisher :
- Informa UK Limited, 2022.
-
Abstract
- A systematic review and meta-analysis of randomized controlled trials (RCTs) were performed to examine treatment-related adverse events (TRAEs) for combination of nivolumab (NIVO) and ipilimumab (IPI) compared to NIVO monotherapy among cancer patients. We searched several databases to identify relevant RCTs. Meta-analysis was performed using random-effects model. In fourteen RCTs included in the study, we found that compared to NIVO monotherapy, combination NIVO + IPI increased the risk of any grade (Risk Ratio (RR) = 1.11), and grade 3 or 4 (RR = 1.95) TRAEs. Compared to NIVO, NIVO + IPI had higher risk for any grade colitis (RR = 4.52), pneumonitis (RR = 3.06), and diarrhea (RR = 1.68).
- Subjects :
- Cancer Research
Oncology
General Medicine
Subjects
Details
- ISSN :
- 15324192 and 07357907
- Volume :
- 40
- Database :
- OpenAIRE
- Journal :
- Cancer Investigation
- Accession number :
- edsair.doi.dedup.....c9dd4c7b10e216b03f15eae4cd7ec200